Meridian Bioscience, Inc. Reports Unaudited Earnings Results for the First Quarter Ended December 31, 2016; Revises Earnings Guidance for the Full Year Ending September 30, 2017
For the full year ending September 30, 2017, management now expects net revenues to be in the range of $193 million to $199 million and per share diluted earnings to be between $0.64 and $0.69. Prior guidance was for revenues in the range of $205 million to $210 million and per share diluted earnings of $0.81 to $0.85. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.4 million at fiscal 2016 year end to approximately 42.6 million at fiscal 2017 year end.